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ABSTRACT
Bone-derived factors that demonstrate extra-skeletal functions, also termed osteokines,
are fast becoming a highly interesting and focused area of cross-disciplinary endocrine
research. Osteocalcin (OCN), fibroblast growth factor-23 (FGF23) and lipocalin-2
(LCN-2), produced in bone, comprise an important endocrine system that is finely
tuned with other organs to ensure homeostatic balance and health. This review aims to
evaluate in vitro evidence of the direct involvement of these proteins in vascular cells and
whether any causal roles in cardiovascular disease or inflammation can be supported.
PubMed, Medline, Embase and Google Scholar were searched for relevant research
articles investigating the exogenous addition of OCN, FGF23 or LCN-2 to vascular
smooth muscle or endothelial cells. Overall, these osteokines are directly vasoactive
across a range of human and animal vascular cells. Both OCN and FGF23 have anti-
apoptotic properties and increase eNOS phosphorylation and nitric oxide production
through Akt signalling in human endothelial cells. OCN improves intracellular insulin
signalling and demonstrates protective effects against endoplasmic reticulum stress in
murine and human endothelial cells. OCNmay be involved in calcification but further
research is warranted, while there is no evidence for a pro-calcific effect of FGF23 in
vitro. FGF23 and LCN-2 increase proliferation in some cell types and increase and
decrease reactive oxygen species generation, respectively. LCN-2 also has anti-apoptotic
effects but may increase endoplasmic reticulum stress as well as have pro-inflammatory
and pro-angiogenic properties in human vascular endothelial and smooth muscle cells.
There is no strong evidence to support a pathological role of OCN or FGF23 in the
vasculature based on these findings. In contrast, they may in fact support normal
endothelial functioning, vascular homeostasis and vasodilation. No studies examined
whether OCN or FGF23may have a role in vascular inflammation. Limited studies with
LCN-2 indicate a pro-inflammatory and possible pathological role in the vasculature
but further mechanistic data is required. Overall, these osteokines pose intriguing
functions which should be investigated comprehensively to assess their relevance to
cardiovascular disease and health in humans.
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INTRODUCTION
The role of the skeleton has greatly evolved from its premise of being a functional tissue
providing primary protection, support, and haematopoietic maintenance. It is now
recognised as an endocrine organ providing exciting opportunities for cross-disciplinary
research. One candidate thread of enquiry is the skeleton’s interaction with the vascular
system. Bone is a highly vascularised tissue, which is important for growth, remodelling and
repair. The endothelial cells lining blood vessels have an important influence on bone cells,
often in a paracrine manner, establishing a ‘bone-vascular axis’ (Brandi & Collin-Osdoby,
2006). This traditionally viewed axis is also evolving to reflect that on the other hand,
secreted, circulating bone-derived factors have direct effects on vascular cells themselves.
Recent research has demonstrated that three ‘osteokines’, namely osteocalcin (OCN),
fibroblast growth factor-23 (FGF23) and lipocalin-2 (LCN-2), comprise an important
endocrine system that is finely tuned with other organs to ensure homeostatic balance
and health (Han et al., 2018). The endocrine functions of OCN have been extensively
reviewed elsewhere (Ducy, 2011; Li et al., 2016; Karsenty, 2017; Han et al., 2018). Briefly,
OCN has been reported to play an active role in the regulation of energy metabolism
by improving glucose tolerance and insulin sensitivity and insulin production (Lee et al.,
2007; Oury et al., 2011; Oury et al., 2013). Elsewhere, OCN−/− male mice were observed
to be poor breeders due to decreased testosterone production and thus has been linked to
fertility (Oury et al., 2011). Interestingly, these OCN−/− mice also displayed behaviours
associated with anxiety and depression and it was demonstrated that OCN can cross the
blood–brain-barrier and enhance monoamine neurotransmitter synthesis, drawing a link
betweenOCN and cognition (Oury et al., 2013). FGF23 is well characterised as the regulator
of phosphate, parathyroid hormone (PTH), and vitamin D in the body which has been
recently reviewed elsewhere (Richter & Faul, 2018). Briefly, in the kidneys, FGF23 increases
phosphate excretion in urine, thus lowering serum concentrations. FGF23 is secreted by
bone following stimulation by increased circulating vitamin D and extracellular phosphate.
FGF23 in turn also supresses 1,25(OH)2D3 production. Thus, a regulatory feedback loop
exists between the kidneys and bone through FGF23. In the kidneys, FGF23 also increases
reabsorption of calcium and sodium (Andrukhova et al., 2014a; Andrukhova et al., 2014b),
while in the parathyroid gland FGF23 supresses PTH production. The endocrine role of
LCN-2 was an interesting discovery through the use of mice lacking LCN-2 in osteoblasts
(Lcn2osb−/−). These mice displayed a decrease in insulin sensitivity and secretion, through
direct activity on pancreatic β-cells, and decreased glucose tolerance (Mosialou et al.,
2017). It has also been shown that LCN-2 crosses the blood brain barrier and activates
melanocortin 4 receptor-dependent appetite signalling in the hypothalamus (Mosialou et
al., 2017).
While these investigations have drawn evidence for the skeletal control of energy
metabolism, mineral homeostasis and much more, the effects of these hormones on the
vasculature itself has also gathered interest. Conflicting observational data exists between
OCN, FGF23 and LCN-2 and markers of cardiovascular disease in humans (Dalal et al.,
2011; Wang, 2012; Millar et al., 2017), which are discussed further within this review.
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In order to assess the relevance of these osteokines to cardiovascular health, we aimed
to provide an analysis of the direct effects of OCN, FGF23 and LCN-2 on micro- and
macro-vascular cells in vitro, and to highlight gaps in the literature which need addressing,
for use by clinicians and researchers.
SURVEY METHODOLOGY
To retrieve articles concerning the exogenous administration of OCN, FGF23 and LCN-2 to
micro- or macro-vascular cells, the following search terms were used for database searching
(PubMed, Embase, Medline, Google Scholar): fibroblast growth factor 23, bone gamma-
carboxyglutamic acid protein, osteocalcin, lipocalin 2, LCN-2, neutrophil gelatinase-
associated lipocalin, NGAL, vascular cell, vascular endothelial cell, and vascular smooth
muscle cell. Additionally, the reference lists of relevant review articles and included articles
were hand-searched for further studies. Searches were carried out up until 20/09/2018.
Retrieved articles were included if they described the exogenous addition of OCN, FGF23 or
LCN-2 to vascular cells in vitro i.e., studies that examined the endogenous over-expression
of these osteokines were excluded, as the results would not be deemed to be bone-derived.
Similarly, passive reporting of osteokines e.g., expression studies, were not evaluated as
this approach excludes the possibility of bone-derived effects and we were interested in
clarifying any direct, causal effects of ‘circulating’ osteokines. Only peer-reviewed, full-text
articles were included, not conference abstracts or articles not in English.
OSTEOCALCIN
Osteocalcin (OCN) has been pioneered as a skeletal hormone for over a decade now,
solidifying a role in influencing energy metabolism (Lee et al., 2007). The mature OCN is a
46 or 49 amino acid protein in mice and humans respectively, predominantly produced by
osteoblasts, and is themost abundant, non-collagenous protein in themineralisedmatrix of
bone (Hauschka, Lian & Gallop, 1975; Price et al., 1976; Celeste et al., 1986; Hauschka et al.,
1989). Due to the presence of 3 glutamic acid residues which may undergo carboxylation,
OCN is present in various forms. These include undercarboxylated OCN with 1 or 2
glutamic acid residues (unOCN), carboxylated OCN with no glutamic acid residues
(cOCN), or uncarboxylated OCN (ucOCN) with 3 glutamic acid residues. Carboxylation
induces a conformational change resulting in a high affinity for calcium ions. Thus, OCN is
also referred to as bone γ-carboxyglutamic acid-containing protein (BGLAP) and binds to
hydroxyapatite crystal lattices present in bone extra-cellular matrix (Hauschka et al., 1989).
unOCN and ucOCN have less affinity to hydroxyapatite and are more readily released into
the circulation. These forms have been the most widely studied and are considered to be
the ‘active’ forms of OCN (Plantalech et al., 1991; Cairns & Price, 1994; Ferron et al., 2010).
Despite the abundance of OCN in bone, its exact role and function in bone reformation
has not been clearly defined. However, serum concentrations of OCN may be used as a
marker of bone turnover as it is widely accepted to be released from mature osteoblasts
during bone formation (Bellows, Reimers & Heersche, 1999).
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Circulating concentrations of OCN
There is currently no consensus on which OCN fragments to measure, and there
are no international or national standards (Lee, Hodges & Eastell, 2000). Total OCN
concentrations have been reported by Hannemann et al. by age and gender (Hannemann
et al., 2013). However, reported serum ucOCN and unOCN concentrations in studies have
largely varied, for example between 0.1 and 0.3 ng/mL, and up to 21.4 ng/mL or 33.0 ng/mL
(Plantalech et al., 1991; Binkley et al., 2000; Iki et al., 2012). OCN concentrations increase
with age but can be reduced by supplementation with vitamin K (Knapen, Hamulyak &
Vermeer, 1989; Plantalech et al., 1991; Knapen et al., 1993). cOCN concentrations have also
not been defined and have been reported to lie around 8–10 ng/mL or higher e.g., 23.9
ng/mL (Luukinen et al., 2000; Tsukamoto et al., 2000; Sugiyama & Kawai, 2001). To add
to the complexity of measuring circulating OCN, only 25% is found intact, and further
additional forms are also present including N-terminal, mid-region, mid-region-C-
terminal, and C-terminal fragments released by proteolytic cleavage (Garnero et al., 1994).
OCN and the vasculature
A number of cross-sectional studies have highlighted associations between OCN
concentrations and atherosclerosis and calcification, however, we found that ameta-analysis
of these data could not provide a conclusive role as study results were mixed and conflicting
with a number of limitations (Millar et al., 2017). Analysing the direct interaction of OCN
and its forms with vascular cells may elucidate whether OCN is a mediator or marker of
vascular calcification or atherosclerosis, and whether it functions to affect vascular cells
independently of its previously noted metabolic influences. Cross-sectional evidence also
exists regarding a role for OCN in inflammation, with some population data highlighting
an inverse association between OCN concentrations and systemic inflammatory makers
such as C-reactive protein and interleukin-6 (Pittas et al., 2009; Chen et al., 2013; Lucey et
al., 2013; Sarkar & Choudhury, 2013; Liao et al., 2015). A recent summary of in vivo ucOCN
treatments in mice and rats concluded that ucOCN protects vascular function and protects
against markers that are commonly associated with the development of atherosclerosis
(Tacey et al., 2018). However, these findings are concomitant with improved metabolic
status, and as such, the establishment of direct effects of OCN and its forms on vascular
cells needs confirmation. The following section aims to summarise in vitro investigations
on the exogenous addition of OCN to vascular endothelial or smooth muscle cells (see
Table 1).
OCN in human and animal cells
Jung et al. (2013) reported an increase in Akt and eNOS phosphorylation and nitric
oxide (NO) production in a PI3-kinase dependent manner in human aortic endothelial
cells (HAECs) when treated with ucOCN (0.3–30.0 ng/mL) (Jung et al., 2013). They
also demonstrated an anti-apoptotic effect of ucOCN, in which 30 ng/mL pre-treatment
prevented linoleic acid induced apoptosis, also via the PI3K/Akt pathway. Similarly, another
study showed an increase in eNOS phosphorylation in HAECs after 30 min incubation
with ucOCN (25 and 100 ng/mL) (Kondo et al., 2016). Interestingly, eNOS phosphorylation
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Table 1 Summary of studies investigating in vitro effects of osteocalcin on human and animal vascular cells.
Study Cell type Type of OCN Concentration Results Conclusions
Idelevich, Rais &
Monsonego-Ornan (2011)
Murine VSMCs Total OCN Unknown OCN was shown to be a glucose
metabolism-modulating factor,
through HIF-1α.
OCN is involved in
glucose-metabolism
Zhou et al. (2013) Murine VECs
and VSMCs
ucOCN 5 ng/mL ucOCN protected against
tunicamycin induced ER
stress and autophagy, and
improved insulin signalling in an
Akt/mTOR/NFκB pathway.
Protective effect of
ucOCN and im-
proved insulin sig-
nalling
Jung et al. (2013) Human AECs ucOCN 0.3–30 ng/mL Increased eNOS and NO, and
prevented linoleic acid induced
apoptosis in PI3-K/Akt depen-
dent manner.
Protective effect of
ucOCN
Dou et al. (2014) HUVECs Total OCN 10–150 ng/mL >30 ng/mL OCN increased
eNOS and Akt phosphorylation
in a time- and dose-dependent
manner.
Potential protective
effect of total OCN
Kondo et al. (2016) Human AECs ucOCN cOCN 25 and 100 ng/mL ucOCN increased eNOS phos-
phorylation after 30 min but
cOCN had no effect.
Potential protective
effect of ucOCN
Guo et al. (2017) HUVECs ucOCN 5 ng/mL In insulin-resistant cells (in-
duced by tunicamycin) ucOCN
improved insulin signal trans-
duction via PI3-K/Akt/NFκB
pathways.
ucOCN is involved in
insulin signalling
Notes.
Abbreviations: OCN, osteocalcin; VECs, vascular endothelial cells; VSMCs, vascular smooth muscle cells; AECs, aortic endothelial cells; HUVECs, human umbilical vein
endothelial cells; ucOCN, uncarboxylated OCN; cOCN, carboxylated OCN; ER, endoplasmic reticulum; mTOR, mechanistic target of rapamycin; NFκB, Nuclear factor-κB;
HIF-1α, hypoxia inducible factor 1−α; PI3-K, phosphoinositide 3-kinase; eNOS, endothelial nitric oxide synthase.
however was not affected by the same concentrations of cOCN (Kondo et al., 2016). Total
OCN (>30.0 ng/mL) was reported to increase Akt and eNOS phosphorylation in human
umbilical vein endothelial cells (HUVECs) in a time- and dose-dependent manner (Dou
et al., 2014). Another study in HUVECs, in which insulin resistance was induced by
tunicamycin, ucOCN (5 ng/mL) improved insulin signal transduction via PI3K/Akt/NF-
κB pathways (Guo et al., 2017). Similarly, mouse vascular endothelial cells (VECs) and
smooth muscle cells (VSMCs) were treated with 5 ng/mL ucOCN which protected against
tunicamycin induced endoplasmic reticulum (ER) stress and autophagy, and improved
insulin signalling in an Akt/mTOR/NF-κB pathway (Zhou et al., 2013).
Idelevich, Rais & Monsonego-Ornan (2011) importantly identified that OCNmay indeed
be an active player in vascular calcification, and not merely a product of differentiated
VSMCs to an osteogenic phenotype. They demonstrated that overexpression of OCN
stimulated glucose utilisation through activation of HIF-1α and promoted mineralisation
and osteogenic differentiation in mouse vascular smooth muscle cells (MOVAS).
Silencing of OCN RNA suppressed these effects. However, this does not distinguish
an effect of osteoblast derived, circulating OCN, but rather locally produced effects from
overexpression. However, when total OCN was exogenously added to wild-type MOVAS,
OCN was shown to be a glucose metabolism-modulating factor, through HIF-1α. No
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investigations have been conducted in human vascular smooth muscle cells to date.
Ultimately, further investigation is needed into the potential direct influence of OCN on
vascular calcification.
Overall, these studies support a hypothesis that OCN, ucOCN particularly, is directly
vasoactive, and can increase nitric oxide via the PI3K/Akt/eNOS signalling pathway,
which ultimately influences vasodilation. Additionally, further atheroprotective effects
are demonstrated through protecting against high fatty acid induced apoptosis and
improving insulin signalling. Although Jung et al. (2013) who used relatively physiological
concentrations demonstrated a potential positive role of ucOCN in HAECs (increasing NO
production and thus improving endothelial function), Idelevich et al. in contrast propose
that OCN stimulates mineralisation and differentiation of mice VSMCs. It remains to
be seen whether these disparities are due to differing effects of forms of OCN within
different cell types and species, incubation timings or origin and concentrations of OCN,
and whether OCN displays various functionalities that cannot be simply categorised into a
good or bad role within the vasculature. The direct role of OCNwithin inflammation in the
vasculature has also not been investigated. These limited studies and abundant questions
signal there is need to clarify the role of physiologically relevant concentrations of OCN
in human vascular cells. Moreover, the effects of both unOCN and cOCN, and potentially
other OCN fragments, must be distinguished and deserves greater focus. Particularly as
unOCN is more likely to be in circulation than fully non carboxylated OCN.
FIBROBLAST GROWTH FACTOR 23
Osteocytes, which are themost abundant bone cell type, are the predominant secretors along
with osteoblasts of fibroblast growth factor 23 (FGF23). FGF23 is the first described bone
hormone and original phosphotonin (Bonewald & Wacker, 2013; Bonnet, 2017). FGF23 is a
251 amino acid protein in humans regulated at gene and protein level (Bonewald & Wacker,
2013). FGF23 is proteolytically cleaved upon secretion. Susceptibility to cleavage is reduced
by O-glycosylation by polypeptide N-acetylgalactosaminyltransferase 3 which allows more
intact, biologically active FGF23 to be secreted (approximately 32 kDa) (Erben, 2017). On
the other hand, phosphorylation of FGF23 promotes cleavage resulting in C-terminus and
N-terminus fragments, whose biological activity is unclear. Soluble or transmembrane
α-Klotho is believed to be the cofactor required to allow for activation of FGF receptors
by FGF23, though in some tissues FGF23 can have klotho independent effects (Urakawa
et al., 2006; Chen et al., 2018; Richter & Faul, 2018). Within bone, the actions of locally
produced FGF23 by osteocytes, as well as osteoblasts, have not been fully elucidated.
Within mice, FGF23 may be a regulator of bone mineralisation in an autocrine/paracrine
manner through inhibiting tissue non-specific alkaline phosphatase (TNAP). This results
in increased pyrophosphate concentrations, likely in a klotho independent manner due to
low concentrations of klotho within bone (Murali et al., 2016; Erben, 2017).
Circulating concentrations of FGF23
FGF23 reaches its target organs through the circulation. Similar toOCN, there is complexity
in measuring FGF23 as there are various presenting forms. Intact FGF23 (iFGF23) is the
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most commonly used measurement, while C-terminus FGF23 (cFGF23) assays can also
be used which measure both iFGF23 and cFGF23 (Smith, 2014). iFGF23 is also subject
to ex vivo degradation and exhibits diurnal variation, while cFGF2 concentrations can be
influenced by iron levels, fibrous dysplasia or familial tumoral calcinosis (Wolf, Koch &
Bregman, 2013; Smith, 2014). In adults, mean cFGF23 has been reported at 49.0 RU/mL,
and iFGF23 at 26.1 pg/mL, but high intra-individual variability exists which limits its
application as a diagnostic or management tool (Smith et al., 2012). Paediatric reference
values have been published for cFGF23 only (22.0–91.0 RU/ml) (Fischer et al., 2012). In
patients with chronic kidney disease (CKD), circulating FGF23 is increased with decreasing
renal function, and can reach up to 1000 times higher than normal levels (Larsson et al.,
2003; Fliser et al., 2007; Gutierrez et al., 2008; Isakova et al., 2011).
FGF23 and the vasculature
A number of epidemiological studies in humans have reported associations between
increased circulating FGF23 concentrations and vascular dysfunction (Mirza et al., 2009a),
vascular calcification (Roos et al., 2008; Desjardins et al., 2012) and increased risk of
cardiovascular disease (Dalal et al., 2011). FGF23 concentrations have been positively
correlated with left ventricular hypertrophy (LVH), which is particularly apparent in
CKD patient cohorts (Hsu &Wu, 2009;Mirza et al., 2009b). Other studies have not shown
an association between FGF23 and vascular calcification or atherosclerotic events in
CKD patients (Seiler et al., 2014; Sarmento-Dias et al., 2016). A recent meta-analysis of
prospective studies concluded that the relationship between FGF23 and cardiovascular
disease risk is unlikely to be causal (Marthi et al., 2018). An established line of thought
is that increased FGF23 may follow, as opposed to initiate, cardiovascular dysregulation
(Stohr et al., 2018). It is likely that negative effects of high FGF23 are due to dysregulated
phosphate metabolism. However, the research surrounding FGF23 is constantly evolving as
the investigation into α-klotho dependent and independent effects continues, as well as the
potential effects of locally produced FGF23 within the cardiovascular system. FGF23 levels
have also been associated with inflammation in CKD patients and in other inflammatory
disorders (David, Francis & Babitt, 2017). The following section reviews the direct effects
of exogenously added FGF23 on vascular cells in order to provide insight into the possible
bone-derived effects as FGF23 travels through the circulation to reach its canonical target
organs (see Table 2).
FGF23 in human and animal cells
In recent years, literature has emerged directed at elucidating the direct effects of FGF23 in
the vasculature. In human aortic smooth muscle cells (HASMCs), 10 ng/mL of exogenous
FGF23 has been shown to increase phosphorylation of ERK (extracellular signal-regulated
kinase) after 10 min in serum-starved cells, which in turn increased production of Early
Growth Response Protein-1 (EGR-1) (Nakahara et al., 2016). Also in human VSMCs,
10 ng/mL of FGF23 increased hydrogen peroxide production and did not induce nitric
oxide (NO) production on its own, however when soluble klotho and phosphate were
also added, NO was increased (Six et al., 2014). In the context of calcification, 5 ng/mL of
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Table 2 Summary of studies investigating in vitro effects of FGF23 on human and animal vascular cells.
Study Cell type Context Concentration Results Conclusions
Lim et al. (2012) Human
ASMCs
Calcification 5 ng/mL FGF23 stimulated proliferation
and phosphorylation of ERK and
AKT in a klotho dependent fash-
ion. Pre-treatment with FGF23
and calcitriol followed by treat-
ment with calcification media in-
hibited development of calcifica-
tion, in a klotho dependent fash-
ion.
Vitamin D receptor
activators can restore
Klotho expression
and unmask FGF23
anti-calcific effects.
Klotho is required for
vascular FGF23 sig-
nalling.
Zhu et al. (2013) Murine
VSMCs
Calcification 10 and 50 ng/mL FGF23 reduced calcium depo-
sition and increased phospho-
rylation of ERK1/2 (but not
AKT). Concomitant exposure to
FGF-23 and an ERK1/2 inhibitor
(PD98059; 10 µM) increased cal-
cification.
FGF23 signalling is
likely to be a protec-
tive mechanism in
calcification.
Lindberg et al. (2013) Bovine
VSMCs
Calcification 0.125–2 ng/mL FGF23 did not modify calcifica-
tion.
No support for a role
of FGF23 in vascular
calcification.
Scialla et al. (2013) Human
VSMCs,
murine
VSMCs
Calcification 1, 2, 10, 20 and
50 ng/mL
FGF23 had no effect on phos-
phate uptake or phosphate-
induced calcification even in
the presence of soluble klotho.
FGF23 did not induce phospho-
rylation of ERK or FRS2α.
No support for a role
of FGF23 in vascular
calcification
Silswal et al. (2014) MurineAECs Normal 9 ng/mL FGF23 increased superoxide lev-
els compared with vehicle which
was inhibited by pre-treatment
with tiron.
FGF23 may reduce
vasorelaxation by de-
creasing NO.
Six et al. (2014) Human
VSMCs,
HUVECs
Normal 10 ng/mL H2O2 concentrations increased
with FGF23 and klotho in
HVSMCs but not in HUVECs.
FGF-23 augmented H202
concentration induced by
phosphate. FGF23 did not
increase NO production in
HUVECs, but FGF23, klotho and
phosphate together, did.
Klotho deficiency
may be deleterious
as appears protec-
tive against increased
ROS production from
FGF23/phosphate.
Nakahara et al. (2016) Human
ASMCs
Normal 10 ng/mL FGF23 increased phosphory-
lated ERK, which subsequently
increased EGR-1 expression.
FGF23 increased
phosphorylated ERK
expression and EGR-
1 in HASMCs.
(continued on next page)
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Table 2 (continued)
Study Cell type Context Concentration Results Conclusions
Richter et al. (2016) Human
CAECs
Normal 10 ng/mL FGF23 increased activation of
FGFR1. Klotho levels were unaf-
fected. FGF23 enhanced Klotho
release and increased levels of
ADAM17. FGF23 increased NO
through Akt and eNOS. Cytoso-
lic ROS increased via Nox2 and
ROS detoxification via SOD2
and CAT. Blocking Klotho re-
sulted in enhanced ROS forma-
tion and reduced NO availabil-
ity.
Excess FGF23 may
promote oxidative
stress and endothelial
dysfunction.
Chung et al. (2017) Human
AECs and
Human
BMECs
Normal 0.5–100 ng/mL FGF23 stimulated cell prolifer-
ation, eNOS, and NO produc-
tion in AECs. High phosphate
mitigated these effects which
could not be rescued by soluble
Klotho. Adding soluble α-Klotho
following α-Klotho knockdown
also did not rescue EC resistance
to FGF23. None of these effects
were observed in HBMECs.
FGF23 promoted
proliferation and
phosphorylation of
eNOS. AECs were
only responsive to
FGF23 in the pres-
ence of α-Klotho syn-
thesized by ECs. HB-
MECs did not re-
spond to FGF23.
Verkaik et al. (2018) Human
MVECs
Normal Approx. 3.2 ng/mL 30 min treatment with FGF23
did not increase ERK phospho-
rylation.
FGF23 did not induce
signal transduction
through ERK.
Notes.
Abbreviations: FGF-23, fibroblast growth factor 23; VSMCs, vascular smooth muscle cells; AECs, aortic endothelial cells; ASMCs, aortic smooth muscle cells; HUVECs,
human umbilical vein endothelial cells; OPG, osteoprotogerin; MVECs, microvascular endothelial cells; BMECs, brain microvascular endothelial cells; CAECs, coronary
artery endothelial cells; FRS2α, FGF receptor substrate 2α; EGR-1, early growth response protein-1; NO, nitric oxide; ECs, endothelial cells; eNOS, endothelial nitric oxide
synthase; ROS, reactive oxygen species; Nox2, NADPH oxidase 2; SOD2, superoxide dismutase 2; CAT, catalase; FGFR1, fibroblast growth factor receptor 1.
FGF23 increased HASMC proliferation after 24 h in cells cultured in calcification media,
and increased phosphorylation of ERK and AKT in a klotho-dependent manner (Lim et al.,
2012). 24 h pre-treatment with FGF23 and calcitriol, followed by culture in calcification
media, deterred calcification in HASMCs in a klotho dependent fashion, but this effect
was not seen with FGF23 alone (without calcitriol) (Lim et al., 2012). Scialla et al. (2013)
did not find any evidence for a pro-calcific effect of FGF23 in HASMCs (1–50 ng/mL),
nor an increase in ERK phosphorylation (Scialla et al., 2013). Reflecting results shown in
human VSMCs, FGF23 alone (10 and 50 ng/mL) reduced calcium deposition in the context
of calcification in murine VSMCs through ERK signalling (Zhu et al., 2013), whereas in
bovine VSMCs 0.2–2.0 ng/mL FGF23 did not modify calcification (Lindberg et al., 2013).
In a study with murine VSMCs no effect of FGF23 on calcification was observed (1–50
ng/mL) (Scialla et al., 2013).
In microvascular endothelial cells, FGF23 did not increase ERK phosphorylation,
nor in human umbilical vein endothelial cells did FGF23 increase hydrogen peroxide
production (Six et al., 2014; Verkaik et al., 2018). In HAECs, FGF23 (50 and 100 ng/mL)
increased proliferation after 48 h, while 10 ng/mL stimulated phosphorylated eNOS and
NO production (Chung et al., 2017). These results were no longer observed following
α-klotho knockdown and could not be rescued by addition of soluble klotho, indicating
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that these effects were dependent on localised endogenous α-klotho production in HAECs.
Interestingly, no increase in proliferation, nor eNOS phosphorylation or NO production
were observed in the same conditions in human brain microvascular cells (Chung et al.,
2017). In coronary artery endothelial cells (HCAECs), Richter et al. (2016) demonstrated
that 10 ng/mL of FGF23 increased expression of the FGF receptor-1, increased eNOS
phosphorylation and NO in an Akt-dependent manner, increased ROS production and
ROS detoxification, and additionally increased secretion of soluble klotho via upregulation
of ADAM17 (Richter et al., 2016). In blocking klotho, the authors further demonstrated
an upregulation of ROS and decrease in NO. In murine aortic endothelial cells, 9 ng/mL
FGF23 significantly increased superoxide levels (Silswal et al., 2014).
These collated results begin to untie whether FGF23 may have any causal effects within
the context of cardiovascular pathologies. A few conclusions can be made including: FGF23
initiates direct effects on vascular cells including SMCs and ECs but actions may be tissue
specific; FGF23 appears to increase eNOS phosphorylation and NO production likely in
an Akt dependent manner, and predominantly in a klotho-dependent manner (perhaps
restricted to locally produced klotho and not systemic circulating klotho); however, FGF23
also appears to increase ROS and oxidative stress, which is counteracted by klotho; within
calcification models, FGF23 increased proliferation of SMCs, but does not appear to
increase calcification and indeed may be anti-calcific. Bringing these results together paints
a conflicting but potential positive role of FGF23 in vascular function. The results presented
encourages the hypothesis that the associations and correlations between FGF23 and CVD
are most likely due to deleterious effects of altered phosphate and mineral metabolism and
indeed that FGF23 levels likely follow, as oppose to direct, cardiovascular disturbances.
It is a complex area, with further discrepancies such as variable physiological and disease
states, deficiency of klotho, origin of secretion of FGF23 and klotho, and many more
factors leaving the role of FGF23 in the vasculature not a simple question to be answered.
Further confirmative examinations are necessary and investigations into whether N- and
C-terminal fragments of FGF23 are additionally biologically active and if so, how they
differ from intact FGF23. Interestingly, any direct pro- or anti-inflammatory properties of
FGF23 on vascular cells have not yet been explored despite accumulating evidence in other
tissues for a role of FGF23 in inflammation (David, Francis & Babitt, 2017).
LIPOCALIN-2
Lipocalin-2 (LCN-2), also referred to as neutrophil gelatinase-associated lipocalin (NGAL)
or 24p3, is the most recently identified osteokine. However, it is debatable whether LCN-2
can be strictly described as such as it is secreted by a wide variety of cell types, and has
indeed been more widely described as an adipokine to date. Despite this, it has recently
been reported to be produced in bone ten-fold more than in white fat, at least in mice, and
it remains to be reported whether this is also the case in humans (Mosialou et al., 2017).
As such, LCN-2 is predominantly an osteoblast and adipocyte derived 25 kDa secreted
glycoprotein which acts as a lipid chaperone positioning itself as a key pro-inflammatory
link between obesity and associated metabolic disorders and vascular disease (Kjeldsen
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et al., 1993; Wang, 2012). It exists in vivo as a monomer, homodimer, or heterodimer by
forming a complex with matrix metalloproteinase-9 (MMP-9) which stabilizes MMP-9
by preventing autodegradation (Kjeldsen et al., 1993; Yan et al., 2001; Chakraborty et al.,
2012). LCN-2 has been identified to mediate an innate immune response to bacteria by
sequestering iron and induces apoptosis in many cell types (Devireddy et al., 2001; Flo et
al., 2004).
Circulating concentrations of LCN-2
LCN-2 is increased in obese individuals, which is presumed derived from increased
adipose tissue and also increased expression from the liver, but may also be due to changes
in skeletal homeostasis which is also altered in obesity (Wang et al., 2007; Luo et al., 2016).
It has been suggested that LCN-2 can be used as a biomarker for early renal injury (Mishra
et al., 2004; Mishra et al., 2005). For example, in children undergoing surgery, those who
did not subsequently develop acute renal injury had LCN-2 serum concentrations <50
ng/mL, but 50% of those who did develop acute renal injury has concentrations >50 ng/mL
(Mishra et al., 2005). In a study of 1,203 Chinese obese and non-obese men, LCN-2 serum
concentrations were in the range 29.3–53.5 ng/mL (Luo et al., 2016). In patients with Type
2 Diabetes, serum levels were significantly higher in those with subclinical atherosclerosis
than those without (112.9 ng/mL versus 77.2 ng/mL) (Xiao et al., 2013). LCN-2 serum
concentrations are also higher in patients with metabolic syndrome compared to those
without (83.2 ng/mL versus 67.5 ng/mL) (Wang et al., 2007).
Lipocalcin-2 and the vasculature
LCN-2 is a novel, debatable osteokine. Examining its effects on vascular cells when
originating from osteoblasts presents a difficult task, requiring for example tissue specific
knock-down studies. Further validation to characterise LCN-2 as an osteokine with more
convincing human data is primarily needed. As LCN-2 has been associated with a stage-
dependent contribution to atherosclerosis, promoting lipotoxicity within the vasculature
in obese states, and causing endothelial dysfunction and cardiovascular complications, it
is important to establish whether bone-derived LCN-2 is a key mediator that could be
therapeutically targeted (Wang, 2012; Amersfoort et al., 2018). LCN-2 is also proposed as a
sensitive marker for cardio-renal disease in patients with acute heart failure (Mishra et al.,
2005; Alvelos et al., 2011).
Most studies to date have focused on observational and epidemiological data on the
involvement of LCN-2 in obesity and diabetic associated vascular complications. It is
currently unfounded to speculate whether these effects are influenced by bone derived
LCN-2. The limited investigations on the direct exogenous addition of this interesting
protein in vascular cells are summarised below and in Table 3.
LCN-2 in human and animal cells
Wang and colleagues, interested in investigating pulmonary hypertension, demonstrated
that in human pulmonary artery smooth muscle cells (HPASMCs), LCN-2 at 10 and
20 ng/mL increased proliferation after 24 hrs (Wang et al., 2015). LCN-2 promoted the
activity of the PI3-K pathway by increasing Akt phosphorylation (3–30 ng/mL) after 24
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Table 3 Summary of studies investigating in vitro effects of LCN-2 on human and animal vascular cells.
Study Cell type Concentration Results Conclusions
Lee et al. (2011) Rat BMVECs 10,000 ng/mL LCN-2 increased expression of
chemokine CXCL10
LCN-2 may promote
chemoattractants and
neuroinflammation
Wang et al. (2014) Human PASMCs 10 ng/mL3–100 ng/mL Decreased serum deprivation in-
duced apoptosis and H2O2 in-
duced apoptosis with LCN-2.
LCN-2 decreased the cleavage
and activity of caspase-3, and ex-
pression of Bax (apoptotic pro-
tein). LCN-2 increased expres-
sion of SOD1/2 and decreased
intracellular ROS.
LCN-2 appears pro-
tective against apop-
tosis and decreased
ROS
Wu et al. (2015) Rat BECs 500–2,000 ng/mL Enhanced Matrigel tube forma-
tion with LCN-2 and migration
of cells via iron and ROS related
pathways
LCN-2 may con-
tribute to neurovas-
cular recovery
Wang et al. (2015) Human PASMCs 3–30 ng/mL LCN-2 increased proliferation, at
least in part via PI3-K signalling
pathway
LCN-2 increased
HPASMC prolifera-
tion
Eilenberg et al. (2016) HUVECs, Human
CASMCs
200 ng/mL, 500 ng/mL
or 1,000 ng/mL
Increased secretion of inflam-
matory markers IL-8, IL-6 and
MCP-1 dose-dependently with
LCN-2
LCN-2 may be pro-
inflammatory
Wang et al. (2017) Human PASMCs 10 ng/mL LCN-2 increased ER stress and
proliferation via increased intra-
cellular iron levels
LCN-2 increased
HPASMC prolifera-
tion and ER stress
Notes.
Abbreviations: LCN-2, lipocalin-2; BMVECs, brain microvascular endothelial cells; BECs, brain endothelial cells; HUVECs, human umbilical vein endothelial cells;
CASMCs, coronary artery smooth muscle cells; PASMCs, pulmonary artery smooth muscle cells; ROS, reactive oxygen species; IL-8, interleukin-8; IL-6, interleukin-6;
MCP-1, monocyte chemoattractant protein-1; SOD1/2, superoxide dismutase 1/2; ER, endoplasmic reticulum.
hrs, which was abrogated by an Akt inhibitor (Wang et al., 2015). This inhibitor also partly
prevented the LCN-2 induced increase in proliferation. Interestingly, this group previously
showed in the same cell type that 10 ng/mL LCN-2 decreased serum deprivation induced
apoptosis after 24 hrs compared to control, and furthermore decreased the susceptibility
of HPASMCs to H2O2 induced apoptosis (Wang et al., 2014). They further showed that
LCN-2 was decreasing the cleavage and activity of caspase-3, and decreasing expression
of Bax, an important pro-apoptotic factor. Finally, they confirmed LCN-2 (3–100 ng/mL
for 24 hrs) increased the expression of superoxide dismutase 1 and 2 (SOD1 and SOD2)
dose-dependently and 10 ng/mL decreased intracellular reactive oxygen species (ROS)
both with and without H2O2. This group went on to show that LCN-2 (10 ng/mL) in
fact promoted endoplasmic reticulum (ER) stress and proliferation within HPASMCs via
increased intracellular iron levels (Wang et al., 2017).
HUVECs and human coronary artery smooth muscle cells (HCASMCs) treated
with LCN-2 (200 ng/mL, 500 ng/mL or 1µg/mL) significantly increased secretion of
inflammatory markers interleukin-8 (IL-8), IL-6 and monocyte chemoattractant protein-1
(MCP-1) in a dose-dependent manner (Eilenberg et al., 2016). Within the central nervous
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system, LCN-2 (10 µg/mL) was shown to increase mRNA expression of C-X-C motif
chemokine 10 in mice brain microvascular endothelial cells (BMVECs), providing
preliminary evidence that LCN-2 may act as a chemoattractant inducer and promote
neuroinflammation (Lee et al., 2011). In another study in rat brain endothelial cells, LCN-2
(0.5–2µg/mL) enhanced angiogenesis, shown throughMatrigel tube formation and scratch
migration, via iron and ROS related pathways (Wu et al., 2015).
Despite the clinical associations between LCN-2 and vascular disturbances, the
mechanisms at a cellular level by physiological concentrations of exogenous LCN-2 have
been largely disregarded and research is warranted. The investigations to date have largely
focused on LCN-2 in the context of pulmonary hypertension and the use of HPASMCs.
Within this cell type LCN-2 is shown to have anti-apoptotic and pro-proliferative effects,
while also decreasing ROS but promoting ER stress. It has also been demonstrated that
LCN-2 may be pro-inflammatory in a number of cells types, which may be viewed as
beneficial in the acute inflammatory response (Castellheim et al., 2009). Concentrations of
LCN-2 used in the studies reviewed have been quite varied (3 ng/mL –10 µg/mL). It is
clear there is a large scope of research yet to be completed in this area to inform researchers
and clinicians about any potential contribution of LCN-2 in vascular physiological and
pathophysiology.
SUMMARY AND CONCLUSIONS
The effects of bone-derived factors on systemic health is an emerging, interesting branch
of endocrinology research. As conflicting epidemiological reports have linked these bone-
derived factors with multiple vascular pathologies such as atherosclerosis and calcification,
there is interest in their therapeutic target potential. In order to derive any causal effects,
it is important to review the basic in vitro science that has been carried out to date. Thus,
this review aimed to collate studies investigating the in vitro effects of OCN, FGF23 and
LCN-2 to clarify whether there is support for a basic biological or pathological role within
the vasculature. Overall, the evidence base points to direct vasoactive properties of the
osteokines OCN, FGF23 and LCN-2 across human and animal cells. Both OCN and FGF23
have been demonstrated to be anti-apoptotic and increase eNOS phosphorylation and
NO production through Akt signalling. Taken together, these findings suggest a role for
these osteokines in supporting normal vascular functionality. OCN has been implicated
in improving insulin signalling, and ensuing protectiveness against ER stress. OCN may
be involved in calcification but further research is warranted, while there is no evidence
at least of a pro-calcific effect of FGF23 in vitro. FGF23 and LCN-2 have been shown
to increase proliferation in some cell types and increase and decrease ROS respectively.
LCN-2 has been shown to have anti-apoptotic effects and may increase ER stress as well
as have pro-inflammatory properties. LCN-2 has also been demonstrated to promote
angiogenesis. There is no strong evidence to suggest a pathological role of OCN or FGF23
in the vasculature, however further research with LCN-2 needs to be completed in order
to better understand its role. Despite the topical area, a number of preliminary questions
remain to be answered. For example, the role of OCN and FGF-23 in inflammation, the
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role of OCN and LCN-2 in calcification, as well as their cellular receptors and related
downstream signalling pathways in vascular cells. Various cleaved forms of the circulating
proteins should also be investigated to assess their biological activity. It is clear that further,
human data should be generated to understand the roles and mechanisms of actions of
these osteokines in physiological and pathophysiological states.
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